These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 12126462

  • 21. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia.
    Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, Diaz E, Castano G.
    Int J Clin Pharmacol Res; 1995; 15(4):159-65. PubMed ID: 8871266
    [Abstract] [Full Text] [Related]

  • 22. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors.
    Más R, Castaño G, Illnait J, Fernández L, Fernández J, Alemán C, Pontigas V, Lescay M.
    Clin Pharmacol Ther; 1999 Apr; 65(4):439-47. PubMed ID: 10223782
    [Abstract] [Full Text] [Related]

  • 23. [A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia].
    Tedeschi-Reiner E, Reiner Z, Romić Z, Ivanković D.
    Lijec Vjesn; 2005 Apr; 127(11-12):273-9. PubMed ID: 16583932
    [Abstract] [Full Text] [Related]

  • 24. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 25. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 26. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.
    Gouni-Berthold I, Berthold HK.
    Am Heart J; 2002 Feb; 143(2):356-65. PubMed ID: 11835043
    [Abstract] [Full Text] [Related]

  • 27. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial.
    Dulin MF, Hatcher LF, Sasser HC, Barringer TA.
    Am J Clin Nutr; 2006 Dec; 84(6):1543-8. PubMed ID: 17158441
    [Abstract] [Full Text] [Related]

  • 28. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 29. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T, Davidson M, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y.
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [Abstract] [Full Text] [Related]

  • 30. Effects of policosanol on postmenopausal women with type II hypercholesterolemia.
    Castaño G, Más R, Fernández L, Fernández JC, Illnait J, López LE, Alvarez E.
    Gynecol Endocrinol; 2000 Jun; 14(3):187-95. PubMed ID: 10923280
    [Abstract] [Full Text] [Related]

  • 31. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 32. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C, Olsson AG.
    Int J Clin Pract Suppl; 2002 Jul 22; (130):27-32. PubMed ID: 12296606
    [Abstract] [Full Text] [Related]

  • 33. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L, Shah A, Davies MJ, Rotonda J, Maccubbin D, Tribble D, Veltri E, Mitchel Y.
    Curr Med Res Opin; 2006 May 22; 22(5):823-35. PubMed ID: 16709304
    [Abstract] [Full Text] [Related]

  • 34. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 22; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 35. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts.
    Menendez R, Fernandez SI, Del Rio A, Gonzalez RM, Fraga V, Amor AM, Mas RM.
    Biol Res; 1994 Jun 22; 27(3-4):199-203. PubMed ID: 8728831
    [Abstract] [Full Text] [Related]

  • 36. Treatment of hypercholesterolemia in NIDDM with policosanol.
    Torres O, Agramonte AJ, Illnait J, Más Ferreiro R, Fernández L, Fernández JC.
    Diabetes Care; 1995 Mar 22; 18(3):393-7. PubMed ID: 7555484
    [Abstract] [Full Text] [Related]

  • 37. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J, Hoffman R, Hanson M, Veltri E.
    Clin Ther; 2008 Dec 22; 30(12):2280-97. PubMed ID: 19167588
    [Abstract] [Full Text] [Related]

  • 38. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
    Castaño G, Fernández L, Mas R, Illnait J, Gámez R, Mendoza S, Mesa M, Fernández J.
    Drugs R D; 2005 Dec 22; 6(4):207-19. PubMed ID: 16050054
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects.
    Greyling A, De Witt C, Oosthuizen W, Jerling JC.
    Br J Nutr; 2006 May 22; 95(5):968-75. PubMed ID: 16611388
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.